Good morning, everyone, and welcome to another working week. Once again, a weekend respite has come and gone. We hope it was invigorating and relaxing, because the usual routine of meetings, deadlines and what-not has returned. As always, we are attacking our own to-do list with help from a cup of stimulation. Please join us, or grab a bottle of water, if you prefer. Meanwhile, here are some tidbits. Have a great day and do keep in touch…
Harvard Pilgrim Health Care has agreed to cover Amgen’s pricey new cholesterol drug in exchange for a discount and potential rebates if the treatment fails to meet performance targets; Pfizer told investors it had a 25.5% global tax rate in 2014, but could have cut its rate to 7.5% by reporting foreign earnings the way most U.S. companies do; and a Delaware federal judge granted a request from AstraZeneca for a temporary restraining order that bars Dr. Reddy’s Laboratories from selling a generic version of the Nexium heartburn drug, because the copy allegedly infringes on the ‘Purple Pill’ trademark.